IHT for Mild Cognitive Impairment

Inclusion Criteria: * Adult men and women ages 55 to 79 years old who have been diagnosed with MCI. * Must be willing to be assigned to either group: treatment or sham-treatment control. * Able to pay multiple visits to the lab for the proposed assessments. * Able to breathe moderately hypoxic air via an air-cushioned, disposable facemask. * To have controlled stabilized chronic conditions of at least 6 months duration, such as hypertension, coronary artery disease, diabetes or metabolic disease, chronic bronchitis, degenerative osteoporosis or arthritis and/or other aging-related chronic conditions. * Must be depression-free at the time of enrollment. * Must have arterial oxygen saturation at or above 95% and cerebral tissue oxygenation at or above 50% at rest. * Woman subject must be post-menopausal. Exclusion Criteria: * Unwilling to sign a written consent to participate in this double-blinded placebo-controlled phase I trial. * Diagnosed with AD-dementia or have impaired independent daily functioning; with MMSE \<20 and/or CDR ≥1. * Unable to visit the lab independently. * Claustrophobic to facemask and hyper-reactive to hypoxia exposure. * Expecting any major surgery or transplant. * Have un-controlled chronic conditions including systolic-diastolic pressures over 150/90 mmHg with medications, diabetes, chronic renal failure (based on the medical history questionnaire), recurrent chest pain, seizures or epilepsies, moderate to severe carotid stenosis or calcification,…